Compact COVID-19 information for clinicians
New short format summarizes the recommendations of the S3 guideline for the inpatient treatment of COVID-19 patients. The "Evidence Brief" was created by the CEOsys research consortium under the coordination of the Medical Center - University of Freiburg
Which treatment can currently be recommended for COVID-19 from a scientific perspective and which cannot? The recently updated S3 guideline on the inpatient treatment of COVID-19 patients addresses this question. The evidence for the guideline was prepared by the research consortium "COVID Evidence Ecosystem" (CEOsys), coordinated by the Medical Center - University of Freiburg. CEOsys has now packaged the findings from the guideline in an abridged version. This "Evidence Brief" enables everyone working in the hospital to get a quick overview of the evidence-based recommendations - from the criteria for transfer to the intensive care unit to follow-up care. Among other things, this showed that The recommendation for dexamethasone is now better supported. Some experimental approaches such as treatments with ivermectin or vitamin D should not be used in the inpatient setting outside of clinical trials for the treatment of COVID-19.
"Lack of time is the biggest barrier when it comes to getting up-to-date information based on reliable evidence. The format of the Evidence Brief brings all the facts that are crucial for treatment into the shortest possible form and thus enables rapid orientation," says Prof. Dr. Jörg Meerpohl, CEOsys spokesperson and Head of the Institute for Evidence in Medicine at the Medical Center - University of Freiburg. The comprehensive evidence analysis behind the guideline - and therefore also behind the Evidence Brief - provides the certainty of acting in line with the latest findings.
About CEOsys
CEOsys is a consortium of 20 university hospitals and several other partner organizations. The idea of the CEOsys evidence ecosystem is to collect the results of scientific studies on the most pressing issues relating to the prevention, treatment and consequences of COVID-19, assess their methodological quality and summarize them in compact evidence syntheses. "As far as the evidence situation allows, concrete recommendations for action will be derived from this, on which medicine, politics and the population can rely. In this way, we also clarify in which areas and for which specific questions there are still gaps in our knowledge," says Meerpohl.
Further information:
Link to the Evidence Brief: https: //covid-evidenz.de/wp-content/uploads/2021/03/CEOsys_EvidenceBrief_S3Behandlung-1.pdf
Link to CEOsys: www.covid-evidenz.de
Contact
Prof. Dr. Jörg Meerpohl
Director
Institute for Evidence in Medicine
Medical Center - University of Freiburg
Phone: 0761 203-6715
sec@ifem.uni-freiburg.de
Back
Medical Center - University of Freiburg
Central Information
Phone: 0761 270-0
info@uniklinik-freiburg.de
For press inquiries:
Corporate Communications
Breisacher Straße 153
79110 Freiburg
Phone: 0761 270-84830
kommunikation@uniklinik-freiburg.de